You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlavopiridol
Accession NumberDB03496  (EXPT00998)
Typesmall molecule
Groupsexperimental, investigational
Description

Flavopiridol is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.

Structure
Thumb
Synonyms
SynonymLanguageCode
AlvocidibNot AvailableINN
Salts
Name/CAS Structure Properties
Flavopiridol hydrochloride
Thumb
  • InChI Key: LGMSNQNWOCSPIK-LWHGMNCYSA-N
  • Monoisotopic Mass: 437.079678201
  • Average Mass: 438.301
DBSALT000800
Brand namesNot Available
Brand mixturesNot Available
Categories
CAS number131740-09-5
WeightAverage: 401.84
Monoisotopic: 401.103000462
Chemical FormulaC21H20ClNO5
InChI KeyBIIVYFLTOXDAOV-YVEFUNNKSA-N
InChI
InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1
IUPAC Name
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-chromen-4-one
SMILES
CN1CC[C@@H]([C@H](O)C1)C1=C(O)C=C(O)C2=C1OC(=CC2=O)C1=CC=CC=C1Cl
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassPhenylpropanoids and Polyketides
ClassFlavonoids
SubclassFlavones
Direct parentFlavonols
Alternative parentsPhenylpiperidines; Chromones; Pyranones and Derivatives; Chlorobenzenes; Phenols and Derivatives; Aryl Chlorides; Tertiary Amines; Secondary Alcohols; Polyols; Enols; Polyamines; Organochlorides
Substituentsphenylpiperidine; chromone; benzopyran; chlorobenzene; pyranone; phenol derivative; benzene; pyran; aryl halide; aryl chloride; piperidine; polyol; tertiary amine; secondary alcohol; polyamine; enol; organohalogen; amine; organochloride; alcohol; organonitrogen compound
Classification descriptionThis compound belongs to the flavonols. These are compounds that has the 3-hydroxyflavone backbone.
Pharmacology
IndicationInvestigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).
PharmacodynamicsNot Available
Mechanism of actionInhibits cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9932
Blood Brain Barrier - 0.557
Caco-2 permeable + 0.6029
P-glycoprotein substrate Substrate 0.9095
P-glycoprotein inhibitor I Non-inhibitor 0.8213
P-glycoprotein inhibitor II Non-inhibitor 0.7929
Renal organic cation transporter Non-inhibitor 0.6429
CYP450 2C9 substrate Non-substrate 0.7975
CYP450 2D6 substrate Non-substrate 0.6651
CYP450 3A4 substrate Substrate 0.6517
CYP450 1A2 substrate Non-inhibitor 0.6845
CYP450 2C9 substrate Non-inhibitor 0.8621
CYP450 2D6 substrate Non-inhibitor 0.7374
CYP450 2C19 substrate Non-inhibitor 0.7358
CYP450 3A4 substrate Non-inhibitor 0.9008
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8937
Ames test Non AMES toxic 0.7686
Carcinogenicity Non-carcinogens 0.9375
Biodegradation Not ready biodegradable 0.9923
Rat acute toxicity 2.7659 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.5312
hERG inhibition (predictor II) Non-inhibitor 0.715
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
Statesolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
water solubility9.40e-02 g/lALOGPS
logP2.81ALOGPS
logP2.48ChemAxon
logS-3.6ALOGPS
pKa (strongest acidic)6.71ChemAxon
pKa (strongest basic)7.36ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count6ChemAxon
hydrogen donor count3ChemAxon
polar surface area90.23ChemAxon
rotatable bond count2ChemAxon
refractivity107.74ChemAxon
polarizability40.85ChemAxon
number of rings4ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterYesChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Kyoung Soon Kim, “Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs.” U.S. Patent US5908934, issued March, 1998.

US5908934
General ReferenceNot Available
External Links
ResourceLink
PubChem Compound5287969
PubChem Substance46507266
BindingDB5655
Therapeutic Targets DatabaseDCL000422
PharmGKBPA452627
HETCPB
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Cyclin-dependent kinase 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cyclin-dependent kinase 2 P24941 Details

References:

  1. Zvelebil MJ: Flavopiridol (Hoechst AG). IDrugs. 1998 Jun;1(2):241-6. Pubmed
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Cyclin-dependent kinase 5

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Cyclin-dependent kinase 5 Q00535 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Cyclin-dependent kinase 9

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Cyclin-dependent kinase 9 P50750 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

4. Cyclin-dependent kinase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Cyclin-dependent kinase 1 P06493 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

5. Cyclin-dependent kinase 6

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Cyclin-dependent kinase 6 Q00534 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

6. Epidermal growth factor receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Epidermal growth factor receptor P00533 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

7. Cyclin-dependent kinase 4

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Cyclin-dependent kinase 4 P11802 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

8. Cyclin-dependent kinase 8

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Cyclin-dependent kinase 8 P49336 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

9. Cyclin-dependent kinase 7

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Cyclin-dependent kinase 7 P50613 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

10. Glycogen phosphorylase, muscle form

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Glycogen phosphorylase, muscle form P11217 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

Transporters

1. ATP-binding cassette sub-family G member 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
ATP-binding cassette sub-family G member 2 Q9UNQ0 Details

References:

  1. Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, Ross DD: Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res. 2003 Aug 15;9(9):3320-8. Pubmed
  2. Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD: Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol. 2003 Dec;64(6):1452-62. Pubmed
  3. Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW, Shao Y, Chen YM, Zang F, Chen ZS: The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep. 2009 Feb;21(2):483-9. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:21